iRadimed Corporation (NASDAQ:IRMD) Short Interest Update

iRadimed Corporation (NASDAQ:IRMD) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 388,071 shares, an increase of 25.1% from the December 15th total of 310,250 shares. Based on an average trading volume of 79,534 shares, the days-to-cover ratio is presently 4.9 days. Currently, 4.8% of the shares of the stock are sold short. Currently, 4.8% of the shares of the stock are sold short. Based on an average trading volume of 79,534 shares, the days-to-cover ratio is presently 4.9 days.

iRadimed Stock Performance

iRadimed stock traded down $0.57 during midday trading on Monday, reaching $102.00. The stock had a trading volume of 67,470 shares, compared to its average volume of 68,618. The stock’s 50-day simple moving average is $94.73 and its 200 day simple moving average is $78.78. iRadimed has a twelve month low of $47.48 and a twelve month high of $103.06. The stock has a market capitalization of $1.30 billion, a PE ratio of 61.82 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities analysts predict that iRadimed will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were paid a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Lake Street Capital reiterated a “buy” rating and issued a $100.00 price target on shares of iRadimed in a report on Monday, November 3rd. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research raised iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Roth Capital set a $90.00 target price on iRadimed in a research note on Friday, October 31st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.33.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the completion of the transaction, the chief executive officer owned 2,272,500 shares of the company’s stock, valued at approximately $221,455,125. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,000 shares of company stock worth $5,451,200 over the last 90 days. Company insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares during the last quarter. Geode Capital Management LLC grew its stake in iRadimed by 6.5% in the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock worth $15,630,000 after purchasing an additional 15,996 shares in the last quarter. Ranger Investment Management L.P. increased its holdings in iRadimed by 7.4% in the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock valued at $12,845,000 after buying an additional 14,730 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after buying an additional 1,821 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.